244 related articles for article (PubMed ID: 24472478)
1. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Vahdat LT; Vrdoljak E; Gómez H; Li RK; Bosserman L; Sparano JA; Baselga J; Mukhopadhyay P; Valero V
J Geriatr Oncol; 2013 Oct; 4(4):346-52. PubMed ID: 24472478
[TBL] [Abstract][Full Text] [Related]
2. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
3. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
Wang J; Fan Y; Xu B
Cancer Chemother Pharmacol; 2010 Aug; 66(3):597-603. PubMed ID: 20490795
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Sparano JA; Vrdoljak E; Rixe O; Xu B; Manikhas A; Medina C; Da Costa SC; Ro J; Rubio G; Rondinon M; Perez Manga G; Peck R; Poulart V; Conte P
J Clin Oncol; 2010 Jul; 28(20):3256-63. PubMed ID: 20530276
[TBL] [Abstract][Full Text] [Related]
6. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN
J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974
[TBL] [Abstract][Full Text] [Related]
8. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L
Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
Valero V; Vrdoljak E; Xu B; Thomas E; Gómez H; Manikhas A; Medina C; Li RK; Ro J; Bosserman L; Vahdat L; Mukhopadhyay P; Opatt D; Sparano JA
Clin Breast Cancer; 2012 Aug; 12(4):240-6. PubMed ID: 22658378
[TBL] [Abstract][Full Text] [Related]
10. Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer.
Li L; Li J; Yang K; Tian J; Sun T; Jia W; Zhang P; Yi K
Future Oncol; 2010 Feb; 6(2):201-7. PubMed ID: 20146579
[TBL] [Abstract][Full Text] [Related]
11. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
[TBL] [Abstract][Full Text] [Related]
12. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
Fornier M
Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.
Roché H; Conte P; Perez EA; Sparano JA; Xu B; Jassem J; Peck R; Kelleher T; Hortobagyi GN
Breast Cancer Res Treat; 2011 Feb; 125(3):755-65. PubMed ID: 21128114
[TBL] [Abstract][Full Text] [Related]
15. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Zhang P; Sun T; Zhang Q; Yuan Z; Jiang Z; Wang XJ; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Peng R; Yan M; Zhang S; Huang J; Tang L; Qiu R; Xu B;
Lancet Oncol; 2017 Mar; 18(3):371-383. PubMed ID: 28209298
[TBL] [Abstract][Full Text] [Related]
16. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
Lechleider RJ; Kaminskas E; Jiang X; Aziz R; Bullock J; Kasliwal R; Harapanhalli R; Pope S; Sridhara R; Leighton J; Booth B; Dagher R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jul; 14(14):4378-84. PubMed ID: 18628451
[TBL] [Abstract][Full Text] [Related]
17. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
18. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
20. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Thomas ES
J Clin Oncol; 2008 May; 26(13):2223. PubMed ID: 18445853
[No Abstract] [Full Text] [Related]
[Next] [New Search]
